Search results for "square"

showing 10 items of 1317 documents

Endothelial function and arterial stiffness indexes in subjects with acute ischemic stroke: Relationship with TOAST subtype.

2017

Abstract Background and aims Only one study has examined endothelial function in subjects with acute ischemic stroke and no study has yet assessed arterial stiffness and reactive hyperemia peripheral arterial tonometry (RH-PAT) in ischemic stroke and its clinical subtypes. Our study aimed to evaluate arterial stiffness and endothelial dysfunction indexes in patients with acute ischemic stroke and the relationship between endothelial dysfunction indexes and arterial stiffness markers and stroke subtypes according to Trial of Org 10172 in Acute Stroke Treatment (TOAST) Classification. Methods We enrolled 98 patients with a diagnosis of acute ischemic stroke and 105 hospitalized patients witho…

MaleSettore MED/09 - Medicina InternaSubtype030204 cardiovascular system & hematologyBrain Ischemia0302 clinical medicineRisk FactorsIschemicOdds RatioMedicineEndothelial dysfunctionEndothelial dysfunctionAcute ischemic strokePulse wave velocityStrokeEndothelial dysfunction; Ischemic; Stiffness; Stroke; Subtypes; TOASTAged 80 and overMiddle AgedTOASTPeripheralStrokeCardiologyFemaleCardiology and Cardiovascular Medicinemedicine.medical_specialtyManometryHyperemiaPulse Wave Analysis03 medical and health sciencesVascular StiffnessPredictive Value of Testsmedicine.arteryInternal medicineHumanscardiovascular diseasesRadial arteryReactive hyperemiaAgedChi-Square Distributionbusiness.industrymedicine.diseaseSurgerybody regionsLogistic ModelsCase-Control StudiesMultivariate AnalysisArterial stiffnessStiffneEndothelium Vascularbusiness030217 neurology & neurosurgery
researchProduct

Lipid-altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk patients with and without metabolic syn…

2011

Metabolic syndrome (MetS) is a clustering of atherosclerotic coronary heart disease risk factors. This post-hoc analysis compared the effects of switching to ezetimibe/simvastatin 10/20 mg or rosuvastatin 10 mg in a cohort of 618 high-risk hypercholesterolaemic patients with ( n=368) and without ( n=217) MetS who had previously been on statin monotherapy. Patients were randomised 1:1 to double-blind ezetimibe/simvastatin 10/20 mg or rosuvastatin 10 mg for 6 weeks. Least squares mean percent change from baseline and 95% confidence intervals in lipid efficacy parameters were calculated for the population and within subgroups. Treatment with ezetimibe/simvastatin was significantly more effect…

MaleSimvastatinSettore MED/09 - Medicina InternaEndocrinology Diabetes and MetabolismEzetimibe Simvastatin Drug CombinationCoronary DiseaseGastroenterologychemistry.chemical_compoundRisk FactorsDrug CombinationAzetidineAnticholesteremic AgentOdds RatioRosuvastatin CalciumMetabolic Syndromeeducation.field_of_studySulfonamidesDrug SubstitutionMetabolic Syndrome XAnticholesteremic AgentsLipidMiddle AgedLipidsEuropeRosuvastatin CalciumDrug CombinationsCholesterolTreatment Outcomelipids (amino acids peptides and proteins)FemaleCardiology and Cardiovascular Medicinemedicine.drugHumanmedicine.medical_specialtyStatinLogistic Modelmedicine.drug_classPopulationHypercholesterolemiaSulfonamideRisk AssessmentEzetimibeDouble-Blind MethodInternal medicineInternal MedicinemedicineHumansRosuvastatinLeast-Squares AnalysiseducationAgedApolipoproteins BLeast-Squares AnalysiAnalysis of VarianceCholesterolbusiness.industryRisk FactorFluorobenzenenutritional and metabolic diseasesCholesterol LDLFluorobenzenesEndocrinologyLogistic ModelsPyrimidineschemistryPyrimidineSimvastatinBiological MarkerAzetidinesEzetimibe/simvastatinHydroxymethylglutaryl-CoA Reductase InhibitorHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessBiomarkersDiabetesvascular disease research
researchProduct

Some findings on zero-inflated and hurdle Poisson models for disease mapping

2018

Zero excess in the study of geographically referenced mortality data sets has been the focus of considerable attention in the literature, with zero-inflation being the most common procedure to handle this lack of fit. Although hurdle models have also been used in disease mapping studies, their use is more rare. We show in this paper that models using particular treatments of zero excesses are often required for achieving appropriate fits in regular mortality studies since, otherwise, geographical units with low expected counts are oversmoothed. However, as also shown, an indiscriminate treatment of zero excess may be unnecessary and has a problematic implementation. In this regard, we find …

MaleStatistics and ProbabilityDatabases FactualEpidemiologyComputer scienceGeographic MappingEstadísticaBiostatisticsPoisson distribution01 natural sciences010104 statistics & probability03 medical and health sciencessymbols.namesakeSpatio-Temporal Analysis0302 clinical medicineNeoplasmsEconometricsHumansPoisson Distribution030212 general & internal medicineLack-of-fit sum of squaresMortality0101 mathematicsProbabilityModels StatisticalBayes TheoremZero (linguistics)SpainMortality datasymbolsMalaltiesFemaleFocus (optics)
researchProduct

PERIPHERAL SURFACE DOSE FROM A LINEAR ACCELERATOR: RADIOCHROMIC FILM EXPERIMENTAL MEASUREMENTS OF FLATTENING FILTER FREE VERSUS FLATTENED BEAMS

2020

Abstract There is a growing interest in the use of flattening filter free (FFF) beams due to the shorter treatment times. The reduction of head scatter suggests a better radiation protection to radiotherapy patients, considering the expected decrease in peripheral surface dose (PSD). In this work, PSD of flattened (FF) and FFF-photon beams was compared. A radiochromic film calibration method to reduce energy dependence was used. PSD was measured at distances from 2 to 50 cm to the field border for different square field sizes, modifying relevant clinical parameters. Also, clinical breast and prostate stereotactic body radiotherapy (SBRT) plans were studied. For square beams, FFF PSD is lowe…

MaleSurface (mathematics)Materials scienceRadiosurgerySquare (algebra)Linear particle accelerator030218 nuclear medicine & medical imaging03 medical and health sciencesRadiation Protection0302 clinical medicineOpticsCalibrationHumansRadiology Nuclear Medicine and imagingRadiochromic filmPhotonsRadiationFlattening filter freeRadiological and Ultrasound Technologybusiness.industryRadiotherapy Planning Computer-AssistedPublic Health Environmental and Occupational HealthRadiotherapy DosageGeneral MedicinePeripheral030220 oncology & carcinogenesisParticle AcceleratorsRadiation protectionbusinessRadiation Protection Dosimetry
researchProduct

Valve prosthesis-patient mismatch: hemodynamic, echocardiographic and clinical consequences

2011

OBJECTIVES: The purpose is to evaluate in vivo at rest and under stress conditions hemodynamic performance of the small size St. Jude Medical Regent (SJMR) prosthetic valve in patients with a body surface area (BSA) of 1.8 ± 0.11 m(2) and to define the role of valve prosthesis- patient mismatch on left ventricular mass regression following aortic valve replacement. METHODS: We evaluated 25 cases (12 males and 13 females, mean age 65.2 ± 8 years) of aortic valve replacement (17 mm SJMR in three cases and 19 mm SJMR in 22 cases). All the patients underwent at rest Doppler echocardiography before and after surgery and both basal and dobutamine stress echocardiography (DSE) at follow-up. The me…

MaleTime FactorsBody Surface Areamedicine.medical_treatmentLeft ventricular maHemodynamicsDoppler echocardiographyVentricular Function LeftValve replacementAortic valve replacementDobutamineCardiac skeletonBody surface areaHeart Valve Prosthesis ImplantationEjection fractionmedicine.diagnostic_testVentricular RemodelingMiddle AgedEchocardiography DopplerTreatment OutcomeAortic ValveHeart Valve ProsthesisCardiologyFemaleHypertrophy Left VentricularCardiology and Cardiovascular MedicineEchocardiography StressPulmonary and Respiratory Medicinemedicine.medical_specialtyProsthesis DesignPreoperative carePredictive Value of TestsInternal medicineProsthesis-patient mismatch; Left ventricular mass; Effective orifice area; DobutaminemedicineHumansAgedRetrospective StudiesChi-Square Distributionbusiness.industryHemodynamicsProsthesis-patient mismatchStroke VolumeSettore MED/23 - Chirurgia CardiacaAortic Valve StenosisRecovery of Functionmedicine.diseaseEffective orifice areaSurgerybusiness
researchProduct

Features Associated with Recurrence Beyond 5 Years After Nephrectomy and Nephron-Sparing Surgery for Renal Cell Carcinoma: Development and Internal V…

2014

Background: Approximately 10-20% of recurrences in patients treated with nephrectomy for renal cell carcinoma (RCC) develop beyond 5 yr after surgery (late recurrence). Objective: To determine features associated with late recurrence. Design, setting, and participants: A total of 5009 patients from a multicenter database comprising 13 107 RCC patients treated surgically had a minimum recurrence-free survival of 60 mo (median follow-up [FU]: 105 mo [range: 78-135]); at last FU, 4699 were disease free (median FU: 103 mo [range: 78-134]), and 310 patients (6.2%) experienced disease recurrence (median FU: 120 mo [range: 93-149]). Interventions: Patients underwent radical nephrectomy or nephron-…

MaleTime FactorsDatabases FactualLymphovascular invasionmedicine.medical_treatmentPredictive Value of Testcomputer.software_genreNephrectomyRisk modelDecision Support TechniqueRisk FactorsRetrospective StudieRenal cell carcinomaOdds Ratiolate recurrencenephrectomyMedicineMultivariate AnalysiFramingham Risk ScoreDatabaseKidney Neoplasmrenal carcinomaPrognostic parametersMiddle AgedNephrectomyKidney NeoplasmsTreatment OutcomeLymphatic MetastasisFemaleRadiologyNephron sparing surgeryPrognostic parameterHumanmedicine.medical_specialtyrenal cell carcinomarecurrenceLogistic ModelTime FactorUrologyReproducibility of ResultLate recurrencecancer-specific mortalityrisk scoreRisk AssessmentDisease-Free SurvivalDecision Support Techniquescancer-specific mortality; late recurrence; nephrectomy; prognostic parameters; renal cell carcinoma; risk scorePredictive Value of TestsLate RecurrenceHumansInternal validationCarcinoma Renal CellProportional Hazards ModelsRetrospective StudiesAgedNeoplasm StagingChi-Square Distributionbusiness.industryProportional hazards modelRisk Factorrenal cell carcinoma; recurrence; Cancer-specific mortality; Late recurrence; Nephrectomy; Prognostic parameters; Risk scoreCancer-specific mortalityReproducibility of ResultsLymphatic MetastasiRetrospective cohort studyOdds ratioprognostic parametersmedicine.diseaseConfidence intervalLogistic ModelsMultivariate AnalysisProportional Hazards ModelRisk scoreNeoplasm GradingNeoplasm Recurrence LocalbusinesscomputerCancer-specific mortality; Late recurrence; Nephrectomy; Prognostic parameters; Renal cell carcinoma; Risk score
researchProduct

Intraoral electrostimulator for xerostomia relief: a long-term, multicenter, open-label, uncontrolled, clinical trial

2012

Objective A previous sham-controlled multinational study demonstrated the short-term efficacy and safety for xerostomia treatment of an intraoral device that delivers electrostimulation to the lingual nerve. The objective of this study was to test the hypothesis that those beneficial effects would be sustained over an 11-month period. Study Design The device was tested on a mixed sample of 94 patients with xerostomia in an open-label, uncontrolled, prospective multicenter trial. Statutory outcome assessments were done at 5th, 8th, and 11th months and analyzed by multiple comparisons. Results Improvements achieved at month 5 from baseline were sustained throughout the follow-up period for th…

MaleTime FactorsDentistryxerostomia; intraoral saliva electrostimulatorPrimary outcomexerostomia genNarinoMedicineProspective StudiesYoung adultProspective cohort studyLikelihood FunctionsMiddle AgedTreatment OutcomeFemaleOral SurgeryOpen labelAdultSleep Wake DisordersSettore MED/50 - Scienze Tecniche Mediche ApplicateElectric Stimulation TherapyLingual NerveXerostomiaSpeech DisordersXerostomíaNervio lingualPathology and Forensic MedicineSettore MED/01 - Statistica MedicaYoung AdultSwallowingstomatognathic systemSettore MED/28 - Malattie OdontostomatologicheMulticenter trialotorhinolaryngologic diseasesHumansRadiology Nuclear Medicine and imagingDentistry (miscellaneous)SalivaAgedChi-Square Distributionbusiness.industryClinical trialstomatognathic diseasesTherapy Computer-AssistedSurgeryEstimulación eléctrica transcutánea del nerviobusinessDeglutition DisordersSecretory RateChi-squared distributionFollow-Up Studies
researchProduct

Papillary muscle relocation in conjunction with valve annuloplasty improve repair results in severe ischemic mitral regurgitation

2012

OBJECTIVE: The incidence of recurrent mitral regurgitation (MR) after restrictive annuloplasty (RA) was 5% to 20% in several reports. There are many opinions in favor of adding subvalvular procedures to RA to reduce the tenting forces and improve the repair results. METHODS: From March 2003 to May 2010, 55 patients with severe ischemic MR who had undergone papillary muscle (PPM) relocation in conjunction with mitral annuloplasty in our institutions were enrolled. The patients were matched 1:1 with those who underwent isolated RA using the propensity score. The mean left ventricular ejection fraction was 42% ± 6%. The mean tenting area and coaptation depth was 3.2 ± 0.6 cm(2) and 1.3 ± 0.2 c…

MaleTime FactorsMitral Valve AnnuloplastyLeftMyocardial IschemiaKaplan-Meier EstimateSeverity of Illness IndexVentricular Function LeftPapillary muscle annuloplasty mitral regurgitationPostoperative ComplicationsRisk FactorsMitral valve annuloplastyAged; Chi-Square Distribution; Disease-Free Survival; Female; Hospital Mortality; Humans; Italy; Kaplan-Meier Estimate; Logistic Models; Male; Matched-Pair Analysis; Middle Aged; Mitral Valve Insufficiency; Myocardial Ischemia; Papillary Muscles; Postoperative Complications; Propensity Score; Proportional Hazards Models; Risk Assessment; Risk Factors; Secondary Prevention; Severity of Illness Index; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Function Left; Mitral Valve AnnuloplastySecondary PreventionClinical endpointVentricular FunctionHospital MortalityMyocardial infarctionEjection fractionIncidence (epidemiology)Mitral Valve InsufficiencyMiddle AgedPapillary MusclesTreatment Outcomemedicine.anatomical_structureItalyCardiologyFemaleCardiology and Cardiovascular MedicinePulmonary and Respiratory Medicinemedicine.medical_specialtyMatched-Pair AnalysisRisk AssessmentDisease-Free SurvivalInternal medicinemedicineHumansPropensity ScorePapillary muscleAgedProportional Hazards ModelsMitral regurgitationChi-Square Distributionbusiness.industryStroke VolumeSettore MED/23 - Chirurgia Cardiacamedicine.diseaseSurgeryLogistic ModelsPropensity score matchingSurgerybusiness
researchProduct

Folfirinox in elderly patients with pancreatic or colorectal cancer-tolerance and efficacy

2016

AIM To study the tolerance and the efficiency of FOLFIRINOX in elderly patients diagnosed with colorectal or pancreatic cancer. METHODS This retrospective study included elderly patients aged over 70 years of age treated at Georges-Francois Leclerc Center by FOLFIRINOX for histological proved colorectal or pancreatic cancer between January 2009 and January 2015. Chemotheapy regimen consisted of oxaliplatin (85 mg/m(2) in over 120 min) followed by leucovorin (400 mg/m(2) in over 120 min), with the addition, after 30 min of irinotecan (180 mg/m(2) in over 90 min) then 5 fluorouracil (5FU) (400 mg/m(2) administred intravenous bolus), followed by 5FU (2400 mg/m2 intraveinous infusion over 46 h)…

MaleTime FactorsOrganoplatinum CompoundsColorectal cancerFOLFIRINOXLeucovorinPooled AnalysisInternational-SocietyKaplan-Meier EstimateOlder PatientsGastroenterology0302 clinical medicineRisk FactorsAntineoplastic Combined Chemotherapy Protocols030212 general & internal medicineAged 80 and overAge FactorsGastroenterologyCommon Terminology Criteria for Adverse EventsGeneral Medicine3. Good healthOxaliplatinTreatment Outcome030220 oncology & carcinogenesisDisease ProgressionFolfirinoxFemale[ SDV.MHEP.HEG ] Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyFluorouracilFranceFolfirinox RegimenColorectal Neoplasmsmedicine.drugmedicine.medical_specialtyOxaliplatin FolfirinoxIrinotecanDisease-Free SurvivalDrug Administration Schedule03 medical and health sciencesPancreatic CancerRetrospective StudyInternal medicinePancreatic cancermedicineHumansChemotherapyGeriatric AssessmentAgedRetrospective StudiesColorectal CancerChi-Square DistributionPerformance statusbusiness.industry[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyElderly Patientsmedicine.diseasePhase-Ii Trial1st-Line TreatmentSurgeryPancreatic NeoplasmsIrinotecanRegimenMultivariate AnalysisCamptothecinOpen-LabelFeasibility TreatmentTomography X-Ray Computedbusiness
researchProduct

Results of mitral valve repair for Barlow disease (bileaflet prolapse) via right minithoracotomy versus conventional median sternotomy: a randomized …

2011

Objective: The results of mitral repair for complex Barlow valves are adequate and support earlier intervention. It is unknown whether these results are reproducible in the context of minimally invasive surgery via right minithoracotomy. Methods: We randomized patients with Barlow mitral disease (bileaflet prolapse) to have conventional open repair via median sternotomy (MS group) or minimally invasive (MI group) repair. Repair was done using polytetrafluoroethylene chordal reimplantation for both leaflets. In the MI group, we adopted right minithoracotomy, peripheral cannulation, external aortic clamping, and surgery under direct vision. Results: Both groups comprised 70 patients. The oper…

MaleTime Factorsmedicine.medical_treatmentKaplan-Meier Estimatelaw.inventionlawRisk FactorsMitral valveCardiac Surgical ProcedureHospital MortalityProspective StudiesUltrasonographyPain PostoperativeMitral Valve ProlapseAtrial fibrillationGenetic Diseases X-LinkedMiddle Agedmedicine.anatomical_structureTreatment OutcomeItalyThoracotomyCardiologyMitral ValveFemaleCardiology and Cardiovascular MedicineHumanPulmonary and Respiratory MedicineAdultReoperationmedicine.medical_specialtyTime FactorContext (language use)Risk AssessmentInternal medicineCardiopulmonary bypassmedicineHumansCardiac Surgical ProceduresMechanical ventilationMitral valve repairMitral regurgitationChi-Square Distributionbusiness.industryRisk FactorPatient SelectionSettore MED/23 - Chirurgia Cardiacamedicine.diseaseSternotomySurgeryProspective StudieMedian sternotomySurgerybusinessThe Journal of thoracic and cardiovascular surgery
researchProduct